Discover
KYMR
Kymera Therapeutics, Inc.
113.37
1 x 108.01
1 x 113.24
bid
ask
+
2.31
2.08%
1 @ 04:00 PM
112.40 -0.97 (0.86%)
| Ytd | 45.70% | |
| 1y | 147.75% |
110.25
day range
113.83
36.65
52 week range
130.05
| Open | 110.25 | Prev Close | 111.06 | Low | 110.25 | High | 113.83 | Mkt Cap | 9.33B |
| Vol | 565.38K | Avg Vol | 797.20K | EPS | -3.53 | P/E | -32.12 | Forward P/E | -27.46 |
| Beta | 1.95 | Short Ratio | 8.01 | Inst. Own | 115.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 94.08 | 200-d Avg | 80.15 | 1yr Est | 125.14 |
| Income Statement | |||
| Total Revenue | 34.37M | ||
| Revenues (USD) | 34.37M | ||
| Gross Profit | 34.37M | ||
| Operating Expenses | 118.52M | ||
| Research and Development Expense | 98.16M | ||
| Selling, General and Administrative Expense | 20.36M | ||
| Operating Income | -84.15M | ||
| Interest Expense | 61.00K | ||
| Net Income | -69.23M | ||
| Net Income Common Stock | -69.23M | ||
| Net Income Common Stock (USD) | -69.23M | ||
| Consolidated Income | -69.23M | ||
| Earnings per Basic Share | -0.71 | ||
| Earnings per Basic Share (USD) | -0.71 | ||
| Earnings per Diluted Share | -0.71 | ||
| Earning Before Interest & Taxes (EBIT) | -69.17M | ||
| Earning Before Interest & Taxes (USD) | -69.17M | ||
| Weighted Average Shares | 97.53M | ||
| Weighted Average Shares Diluted | 97.53M | ||
| Balance Sheet | |||
| Cash and Equivalents | 149.90M | ||
| Cash and Equivalents (USD) | 149.90M | ||
| Investments | 1.40B | ||
| Investments Current | 506.84M | ||
| Investments Non-Current | 894.72M | ||
| Current Assets | 677.43M | ||
| Property, Plant & Equipment Net | 83.35M | ||
| Total Assets | 1.67B | ||
| Debt Current | 13.73M | ||
| Total Debt | 80.47M | ||
| Current Liabilities | 62.64M | ||
| Debt Non-Current | 66.74M | ||
| Total Liabilities | 129.38M | ||
| Accumulated Retained Earnings (Deficit) | -1.14B | ||
| Accumulated Other Comprehensive Income | -4.19M | ||
| Shareholders Equity | 1.54B | ||
| Shareholders Equity (USD) | 1.54B | ||
| Assets Non-Current | 991.58M | ||
| Total Debt (USD) | 80.47M | ||
| Liabilities Non-Current | 66.74M | ||
| Trade and Non-Trade Payables | 12.84M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.02M | ||
| Net Cash Flow from Financing | 18.77M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -212.91M | ||
| Capital Expenditure | -434.00K | ||
| Issuance (Purchase) of Equity Shares | 19.19M | ||
| Issuance (Repayment) of Debt Securities | -425.00K | ||
| Net Cash Flow from Investing | -142.84M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -142.41M | ||
| Net Cash Flow from Operations | -88.84M | ||
| Share Based Compensation | 16.01M | ||